Figure 6.

Confirmation of anti-cancer effect targeting human colorectal cancer (CRC). (A,B) The decrease in the CRC cell viability following dose-dependent CaLac treatment. (C) Inhibition of capillary-like tubular structures of human umbilical vein endothelial cells (HUVEC). Scale bars, 200 µm. (D) Inhibition of wound healing properties. ). Scale bars, 200 µm. (E) Anti-cancer effect on heterotopic xenograft model. (F) Anti-metastatic effect targeting the liver. Three individual samples were analyzed. Scale bars, 1 cm. ** p < 0.001 and * p < 0.05 vs. Untreated. Results are presented as mean ± standard deviation.